Who We are

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders.

Plexision's first patented product, the Pleximmune^TM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells.

Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh.